Why the study?
Does pharmacy refill assessment of antihypertensive medication adherence predict incident CVD differently than self-report assessment?
Does pharmacy refill assessment of antihypertensive medication adherence predict incident CVD differently than self-report assessment?
Pharmacy refill data is a more reliable predictor of incident cardiovascular disease than self-reported adherence in patients taking antihypertensive medications.
Pharmacy refill adherence may better predict CVD risk than self-report; leaves open whether it should guide practice or trial endpoints.
While both adherence measures were associated with BP control, pharmacy refill but not self-report antihypertensive medication adherence was associated with incident CVD. The differences in these associations may be because of the distinctions in what each adherence measure assesses.
No takes yet. Share an insight, caveat, or question.
Krousel‐Wood et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: